Holen Sie sich die Stockscreener-App
0.9729
2.71%
-0.0271
Handel nachbörslich:
1.00
0.0271
+2.79%
Schlusskurs vom Vortag:
$1.00
Offen:
$1.01
24-Stunden-Volumen:
1.75M
Relative Volume:
1.07
Marktkapitalisierung:
$112.20M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.5896
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
-9.92%
1M Leistung:
-8.22%
6M Leistung:
+2.41%
1J Leistung:
-72.36%
1-Tages-Spanne:
$0.95
$1.015
1-Wochen-Bereich:
$0.95
$1.10
52-Wochen-Spanne:
$0.6611
$4.20
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Vergleichen Sie FATE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
0.9729 | 118.79M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Volume spikes in Fate Therapeutics Inc. stock – what they meanMarket Sentiment Summary & High Conviction Buy Zone Picks - Newser
Does Fate Therapeutics Inc. show high probability of rebound2025 Geopolitical Influence & High Accuracy Investment Signals - Newser
Detecting support and resistance levels for Fate Therapeutics Inc.Weekly Stock Recap & Target Return Focused Picks - Newser
Can volume confirm reversal in Fate Therapeutics Inc.2025 Fundamental Recap & Technical Buy Zone Confirmation - Newser
Institutional scanner results for Fate Therapeutics Inc.Trade Volume Summary & Growth Focused Entry Point Reports - Newser
Will Fate Therapeutics Inc. bounce back from current supportPortfolio Risk Report & Weekly High Conviction Trade Ideas - Newser
Is Fate Therapeutics Inc. trending in predictive chart modelsWeekly Trade Recap & Real-Time Stock Movement Alerts - Newser
Can machine learning forecast Fate Therapeutics Inc. recoveryPrice Action & Stock Market Timing Techniques - Newser
Fate Therapeutics' Equity Incentive Strategy and Its Implications for Talent Retention and Long-Term Value Creation - AInvest
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics shares rise 3% after-hours following new employee inducement grants. - AInvest
Is Fate Therapeutics Inc. stock entering bullish territoryTrade Exit Summary & Weekly High Potential Alerts - Newser
Does Fate Therapeutics Inc. align with a passive investing strategyInflation Watch & Consistent Income Trade Recommendations - khodrobank.com
Heatmap analysis for Fate Therapeutics Inc. and competitorsJuly 2025 WrapUp & Fast Gain Stock Tips - Newser
What are Fate Therapeutics Inc.’s recent SEC filings showingQuarterly Profit Review & Breakout Confirmation Trade Signals - khodrobank.com
Using data models to predict Fate Therapeutics Inc. stock movementJuly 2025 Macro Moves & Weekly High Return Stock Forecasts - Newser
What MACD and RSI say about Fate Therapeutics Inc.Quarterly Profit Report & AI Powered Market Trend Analysis - Newser
Why Fate Therapeutics Inc. stock attracts strong analyst attentionTrade Analysis Summary & Short-Term Trading Alerts - Newser
Published on: 2025-09-03 09:36:15 - Newser
Has Fate Therapeutics Inc. found a price floorWall Street Watch & Risk Managed Trade Strategies - Newser
Will Fate Therapeutics Inc. stock hit new highs in YEARJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - khodrobank.com
Chart overlay techniques for tracking Fate Therapeutics Inc.2025 Technical Patterns & Entry and Exit Point Strategies - Newser
Building trade automation scripts for Fate Therapeutics Inc.M&A Rumor & Low Risk Entry Point Tips - Newser
Backtesting results for Fate Therapeutics Inc. trading strategiesMarket Trend Review & Smart Allocation Stock Reports - Newser
Market reaction to Fate Therapeutics Inc.’s recent newsJuly 2025 Recap & High Accuracy Investment Entry Signals - Newser
Visual trend scoring systems applied to Fate Therapeutics Inc.July 2025 Levels & Daily Oversold Bounce Ideas - Newser
Is Abeona Therapeutics Inc. attractive at current valuation2025 Macro Impact & Consistent Return Investment Signals - khodrobank.com
What is Fate Therapeutics Inc. s 5 year growth outlookTrade Volume Report & Weekly Breakout Stock Alerts - khodrobank.com
Is Fate Therapeutics Inc. forming a bottoming baseJuly 2025 Sector Moves & Stock Portfolio Risk Management - Newser
Fate Therapeutics Inc. Crosses 200 Day MA — Signal or Noise getLinesFromResByArray error: size == 0 - 강소기업뉴스
Will Fate Therapeutics Inc. stock go up soon2025 Volume Leaders & Technical Analysis for Trade Confirmation - Newser
Comparing Fate Therapeutics Inc. in custom built stock radarsRisk Management & Weekly Top Performers Watchlists - Newser
What is Fate Therapeutics Inc.’s valuation compared to sectorMarket Activity Report & Fast Entry Momentum Alerts - khodrobank.com
Published on: 2025-09-01 01:36:52 - Newser
Fate Therapeutics Inc. stock trend forecastEarnings Summary Report & Community Driven Trade Alerts - Newser
Understanding Fate Therapeutics Inc.’s price movementMarket Movement Recap & Real-Time Buy Zone Alerts - Newser
How to interpret RSI for Fate Therapeutics Inc. stockLong Setup & Advanced Technical Analysis Signals - Newser
Tick level data insight on Fate Therapeutics Inc. volatilityWeekly Trade Report & Low Risk Investment Opportunities - Newser
Fate Therapeutics Inc. stock momentum explainedPortfolio Gains Report & Consistent Income Trade Ideas - Newser
RSI Crosses Above 30 for Fate Therapeutics Inc. — Reversal in Sight2025 Key Lessons & Fast Gain Swing Alerts - beatles.ru
Can technical indicators confirm Fate Therapeutics Inc.’s reversalJuly 2025 PostEarnings & Daily Price Action Insights - Newser
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fate Therapeutics Inc-Aktie (FATE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
Aug 04 '25 |
Sale |
1.06 |
14,466 |
15,396 |
334,898 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):